Navigation Links
Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Date:10/1/2013

NEW YORK, Oct. 1, 2013 /PRNewswire/ -- Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the final closing of a Series A financing raising $8 million in gross proceeds.  The offer was oversubscribed and Laidlaw & Company (UK) Ltd. acted as the exclusive placement agent.   

The company intends to use the Series A proceeds to continue the development of its product pipeline and for general corporate activities.  "This impressive response from investors clearly shows the potential of our diversified product portfolio of drug candidates aimed to address the significant unmet medical need in chronic pain," said Sergio Traversa, CEO of Relmada.  Based on this successful offering, we plan to complete the required steps for LevoCap ER to enter Phase III of development, d-methadone to enter Phase IIb, MepiGel and BuCap to start the pilot PK studies and to prepare the company for a public transaction in the first half of 2014.

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company with a diversified portfolio of four products and a deep early stage pipeline for the treatment of pain.  Relmada's strategy focuses on two complementary pillars: the improvement of proven drug candidates with novel delivery methods and pharmaceutical compositions and the development of d-methadone as an innovative NMDA (N-Methyl-D-aspartate) inhibitor platform. 

The Company is currently developing several drug candidates including: LevoCap ER, its abuse resistant, once–a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for diabetic painful neuropathy (DPN); BuCap, its oral dosage form of the opioid analgesic buprenorphine; MepiGel, its FDA Orphan Drug designated topica
'/>"/>

SOURCE Relmada Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... doubled Hectorol sales , Middleton, Wis. Bone ... the work of University of Wisconsin-Madison professor Hector DeLuca, reported ... said its sales of the drug Hectorol were $19.6 million, ... million, despite large theft , Neenah, Wis. ...
... Actor Michael J. Fox plans to visit the Waisman ... Jim Doyle and Fox will hold a media event ... for biotechnology research in Wisconsin. , ,In November, Doyle ... biotechnology and stem cell research, including a collective $750 ...
... wrote about the importance of transparency, which I described ... and maybe even personal perspectives" so that "intelligent consumers ... and write." , ,This transparency puts content in context, ... where the rules of reportorial journalism, more often than ...
Cached Biology Technology:Michael J. Fox coming to UW Waisman Center 2Corporations and blogging 2Corporations and blogging 3
(Date:4/23/2014)... This news release is available in French ... , Montreal, 23 April 2014Today, the CEC released ... A Binational Collaborative Approach to Conservation, which identifies 29 ... States-Mexico border that includes 11 different protected areas in ... features unique, highly diverse arid and semi-arid habitats inhabited ...
(Date:4/23/2014)... NY. (Apr. 23, 2014) People who have had ... to restore neurological function. However, a study conducted in ... of Cell Transplantation , but is currently freely ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group of ... (PBSCs) injected directly into the brain and a similar ...
(Date:4/23/2014)... in Buenos Aires yesterday, Argentina joins the European ... state. The move strengthens the ties between the ... grants Argentinian scientists access to EMBL,s world-class facilities ... "Ever since its inception, fostering excellent life science ... the core of EMBL,s mission," says EMBL Director ...
Breaking Biology News(10 mins):Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
... new protein produced excessively in malignant melanoma, a discovery ... dramatically among young women. The protein, IMP-3, is ... the most dangerous types of skin cancer, and in ... predict called thin melanomas. The finding offers a potential ...
... DAGAN, ISRAEL - Table grapes are subject to serious water ... vine to dinner tables around the world. Mold and browning ... grape quality during shipping and storage in retail produce sections. ... one way of ensuring that consumers get fresh, appealing fruits. ...
... Washington, DCMay 28, 2008The 2008 American Society ... the Year Award is presented to Vctor ... of Biotechnology of the Spanish Research Council, ... microbiologist who has exhibited exemplary leadership in ...
Cached Biology News:As rates rise, researchers find better way to identify melanoma 2As rates rise, researchers find better way to identify melanoma 3Fresh from the grapevine to the table 2American Society for Microbiology honors Victor de Lorenzo 2
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
Biology Products: